Moderna, Inc. — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-03-03

Reporting Person: SAGAN PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-03	Common Stock	P	31620	$31.76	Acquired	312027	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	703	Direct
Common Stock	14951	Indirect
Common Stock	166452	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.46 to $31.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2: This balance reflects the transfer of 90,000 shares of the Issuer's common stock from The Paul Sagan Revocable Trust to The Chatham Trust on November 21, 2024.

F3: Erwin Park LLC is an investment vehicle owned by the Reporting Person's children. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.